$10.47 Million in Sales Expected for Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) This Quarter

Wall Street brokerages expect Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS – Get Rating) to post sales of $10.47 million for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Pieris Pharmaceuticals’ earnings, with the highest sales estimate coming in at $17.70 million and the lowest estimate coming in at $3.24 million. Pieris Pharmaceuticals reported sales of $3.29 million during the same quarter last year, which indicates a positive year-over-year growth rate of 218.2%. The business is scheduled to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Pieris Pharmaceuticals will report full-year sales of $45.71 million for the current year, with estimates ranging from $20.71 million to $70.70 million. For the next year, analysts anticipate that the firm will post sales of $47.01 million, with estimates ranging from $9.32 million to $84.70 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Pieris Pharmaceuticals.

Pieris Pharmaceuticals (NASDAQ:PIRS – Get Rating) last posted its earnings results on Tuesday, May 10th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.05. Pieris Pharmaceuticals had a negative return on equity of 92.04% and a negative net margin of 175.99%. During the same period last year, the company posted ($0.07) EPS.

A number of research analysts have weighed in on the company. StockNews.com initiated coverage on Pieris Pharmaceuticals in a research note on Thursday, March 31st. They set a “hold” rating on the stock. Zacks Investment Research raised Pieris Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 target price on the stock in a research report on Tuesday, May 17th.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Hsbc Holdings PLC increased its holdings in Pieris Pharmaceuticals by 55.6% in the 1st quarter. Hsbc Holdings PLC now owns 20,556 shares of the biotechnology company’s stock valued at $63,000 after purchasing an additional 7,343 shares in the last quarter. Royal Bank of Canada increased its holdings in Pieris Pharmaceuticals by 226.0% in the 2nd quarter. Royal Bank of Canada now owns 12,975 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 8,995 shares in the last quarter. Cetera Advisors LLC acquired a new stake in Pieris Pharmaceuticals in the 3rd quarter valued at $52,000. Oppenheimer & Co. Inc. acquired a new stake in Pieris Pharmaceuticals in the 1st quarter valued at $32,000. Finally, Blair William & Co. IL increased its holdings in Pieris Pharmaceuticals by 9.1% in the 1st quarter. Blair William & Co. IL now owns 128,745 shares of the biotechnology company’s stock valued at $390,000 after purchasing an additional 10,760 shares in the last quarter. Hedge funds and other institutional investors own 65.30% of the company’s stock.

Shares of Pieris Pharmaceuticals stock opened at $1.75 on Tuesday. Pieris Pharmaceuticals has a fifty-two week low of $1.61 and a fifty-two week high of $6.15. The firm has a market cap of $129.68 million, a PE ratio of -2.54 and a beta of 1.19. The business’s fifty day moving average is $2.77 and its two-hundred day moving average is $3.20.

Pieris Pharmaceuticals Company Profile (Get Rating)

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids.

Read More